CANTA Stock Overview
A biotechnology company, develops antibody-based treatments for life threatening diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Cantargia AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 3.46 |
| 52 Week High | SEK 5.40 |
| 52 Week Low | SEK 2.56 |
| Beta | 1.75 |
| 11 Month Change | -18.46% |
| 3 Month Change | -1.31% |
| 1 Year Change | -30.57% |
| 33 Year Change | -84.06% |
| 5 Year Change | -78.47% |
| Change since IPO | -61.53% |
Recent News & Updates
Recent updates
We're A Little Worried About Cantargia's (STO:CANTA) Cash Burn Rate
Apr 25
Is Cantargia (STO:CANTA) In A Good Position To Deliver On Growth Plans?
Jun 28We Think Cantargia (STO:CANTA) Can Afford To Drive Business Growth
Mar 08Is Cantargia (STO:CANTA) In A Good Position To Invest In Growth?
Nov 22An Intrinsic Calculation For Cantargia AB (publ) (STO:CANTA) Suggests It's 47% Undervalued
May 31Here's Why We're Not Too Worried About Cantargia's (STO:CANTA) Cash Burn Situation
May 02Is Cantargia (STO:CANTA) In A Good Position To Invest In Growth?
Jan 10We Think Cantargia (STO:CANTA) Can Easily Afford To Drive Business Growth
Sep 20Shareholder Returns
| CANTA | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -8.7% | -5.4% | -4.2% |
| 1Y | -30.6% | 18.1% | 12.5% |
Return vs Industry: CANTA underperformed the Swedish Biotechs industry which returned 18.1% over the past year.
Return vs Market: CANTA underperformed the Swedish Market which returned 12.5% over the past year.
Price Volatility
| CANTA volatility | |
|---|---|
| CANTA Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in SE Market | 12.2% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: CANTA's share price has been volatile over the past 3 months.
Volatility Over Time: CANTA's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 23 | Goran Forsberg | cantargia.com |
Cantargia AB (publ), a biotechnology company, develops antibody-based treatments for life threatening diseases. The company is developing CAN04 (nadunolimab), an interleukin-1 receptor accessory protein (IL1RAP) binding antibody, which is in Phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in preclinical phase for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops CANxx, an IL1RAP-based antibody platform.
Cantargia AB (publ) Fundamentals Summary
| CANTA fundamental statistics | |
|---|---|
| Market cap | SEK 635.92m |
| Earnings (TTM) | -SEK 241.07m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.6x
P/E RatioIs CANTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CANTA income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 241.07m |
| Earnings | -SEK 241.07m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 28, 2024
| Earnings per share (EPS) | -1.31 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CANTA perform over the long term?
See historical performance and comparison